|
Sep 7
|
DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
|
|
Jul 20
|
UPDATE 2-Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment
|
|
Jul 20
|
VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
|
|
May 25
|
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA
|
|
May 22
|
Japan's Daiichi Sankyo invests $80 million to expand Brazilian plant
|